Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Background HAART has improved AIDS-associated morbidity and mortality PowerPoint Presentation
Download Presentation
Background HAART has improved AIDS-associated morbidity and mortality

Background HAART has improved AIDS-associated morbidity and mortality

565 Vues Download Presentation
Télécharger la présentation

Background HAART has improved AIDS-associated morbidity and mortality

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH. • Background • HAART has improved AIDS-associated morbidity and mortality • Given the bimodal mortality distribution in HIV-infected children, it is important to evaluate temporal effects of HAART among a pure birth cohort with long-term, prospective follow-up. • Methods • CDC-sponsored multi-center, prospective birth cohort study of HIV-exposed infants enrolled 1986-1999 to monitor MTCT and pediatric HIV progression. • HIV-infected children followed through 4/04 • Average annual mortality calculated for no/mono-therapy (≤12/31/90), mono/dual-therapy (1/1/91-12/31/96) and HAART eras (≥1/1/97) • Mortality trends evaluated using survival analysis and Poisson regression • Extended Cox proportional-hazards regression models (Cox PH) estimated the effect of HAART on mortality

  2. Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH. • Results • Among 364 children, 98 died 61 were < 2 y/o; 18 more were between 2 – 3 y/o. • Ten-year survival of those who ever received HAART and of non-HAART recipients was 94% and 45% (P<0.05) Survival probability among HAART recipients (defined by age of initiation of HAART) vs. non-recipients

  3. Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH. • Results (cont’d) • HAART-associated declines in mortality remained significant after controlling for birth year, CD4%, anthropometrics (HAZ & WAZ) and maternal CDC classification (Cox PH model, HR=0.25: 95%CI 0.08-0.76) • Conclusions • A significant decrease in annual mortality and a prolongation in survival were seen among HAART recipients in this U.S. perinatal cohort of HIV-infected children • Advances in antiretroviral therapy led to commensurate improvements in crude annual mortality rates (Log-Rank test P<0.05) • Using Poisson regression to adjust for gender, race, prematurity, era-entry age, AZT prophylaxis, maternal AIDS class and IVDU hx, the mortality rate ratios in the no/mono- and mono/dual- therapy eras were ~30-fold (P<0.01) and ~9-fold(P<0.01) higher, respectively, than in the HAART era